Healthcare Providers and Services
Company Overview of City Of Hope
City of Hope, a nonprofit public benefit corporation, operates City of Hope National Medical Center (the Center), City of Hope Medical Foundation, and Beckman Research Institute of the City of Hope. The Center operates a 186-bed tertiary referral center primarily for the treatment of cancer, diabetes, and other life-threatening diseases in Duarte, California. The company was founded in 1913 and is based in Duarte, California.
1500 East Duarte Road
Duarte, CA 91010
Founded in 1913
Key Executives for City Of Hope
Chief Executive Officer and President
Chief Operating Officer and Executive Vice President
Chief Scientific Officer and Provost
Senior Vice President of Research Operations
Compensation as of Fiscal Year 2015.
City Of Hope Key Developments
Victoria L. Seewaldt Joins City of Hope as the Ruth Ziegler Chair in Population Sciences
Sep 29 15
Nationally breast cancer and ovarian cancer specialist Victoria L. Seewaldt, M.D., has joined City of Hope as the Ruth Ziegler Chair in Population Sciences. An expert in cancer prediction and prevention, Seewaldt will advance the institution’s efforts to ensure its research reflects and represents the diversity within City of Hope’s community. A specialist in developing risk models for aggressive cancers, particularly in women of color, Seewaldt will also serve as the associate director of the comprehensive cancer center. Seewaldt comes to City of Hope from Duke University, where she was a professor of medicine and leader of the Comprehensive Cancer Breast and Ovarian Cancer Program. She also founded the institution’s community outreach program for underserved women. Seewaldt will lead the Breast Cancer Early Detection and Health Disparities Program at City of Hope, operating a clinic for women at high risk of breast and ovarian cancers and working to better understand which cancers can be predicted, and thus prevented. She will also work with City of Hope’s community sites to gather information on the areas’ diverse population in order to gain a more thorough understanding of risk and disease progression.
Seewaldt will emphasize clinical trials that focus on keeping high-risk women healthy, as opposed to those that emphasize intervention through medications, which can have serious side effects. She also will work to provide women in the community with health education and improved access to breast cancer screenings and treatment, as well as provide mentorship of young minority scholars.
Center for Gene Therapy Names John Zaia as Director at City of Hope
Jun 17 15
John A. Zaia, M.D., has been named director of the Center for Gene Therapy within City of Hope’s new Hematologic Malignancies and Stem Cell Transplantation Institute. Internationally known and respected for his groundbreaking research into potential gene therapy treatments for HIV, Zaia will maximize the potential of gene therapy not just for HIV, but also for cancer and other diseases as City of Hope expands its commitment to this revolutionary field of research.
City of Hope and Fortress Biotech Reach an Agreement to Form New Subsidiary Company, Diavax Biosciences
May 4 15
City of Hope and Fortress Biotech have reached an agreement to form a new subsidiary company, DiaVax Biosciences, that will develop two novel vaccines against cytomegalovirus infection, a life-threatening illness in people with weakened or underdeveloped immune systems, such as cancer patients and developing fetuses. Enlisting the defensive power of the immune system, the vaccines could open the door to a new way of treating a devastating opportunistic infection affecting hundreds of thousands worldwide. The vaccines Triplex and PepVax will be the subject of multi-site Phase II clinical trials, one of which already has begun enrollment (PepVax). The other (Triplex) will begin enrollment in fall of 2015. Supported by the National Cancer Institute, those trials could ultimately lead to even greater impact for City of Hopeâ€™s research. DiaVax has entered into an option with City of Hope for exclusive worldwide rights to a universal immunotherapeutic vaccine, called Pentamer, that could prevent the transmission of CMV in utero. Such transmission leads to thousands of cases of irreversible brain damage every year.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 26, 2014